iPredict Eye Screening vs PMcardio
AI Verdict
Choose iPredict Eye Screening if…
Choose iPredict Eye Screening if your primary care practice or clinic needs an efficient, AI-powered solution for early detection of multiple retinal diseases like Diabetic Retinopathy, AMD, and Glaucoma, especially for patients aged 50 and older or those with diabetes. It's ideal for quick, non-invasive screenings that provide fast results and can also offer risk prediction for systemic diseases such as stroke and heart attack.
View iPredict Eye Screening →Choose PMcardio if…
Choose PMcardio if your healthcare setting, particularly in emergency medicine, cardiology, or internal medicine, requires rapid and highly accurate AI-powered interpretation of ECGs for over 50 cardiac conditions. It's well-suited for situations where quick, confident clinical decisions are critical, such as detecting STEMI/OMI and reduced LVEF, and can be deployed via mobile app or integrated with existing EHR/CVIS systems.
View PMcardio →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | iPredict Eye Screening | PMcardio |
|---|---|---|
| Pricing | Contact for pricing | Freemium |
| Deployment | Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps. | Mobile app (iOS and Android), Web platform, Enterprise integrations with EHR/CVIS and EMS systems |
| FDA Status | 1 AI-estimated | Pending AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
PMcardioPMcardio offers a mobile app and web platform, allowing for immediate use without IT integration, which suggests a lower barrier to entry and higher accessibility for individual clinicians. iPredict Eye Screening, while touting an advanced touchscreen interface and ease of operation, is primarily cloud-based and integrated with EHR/telemedicine, implying a more complex setup for initial use. PMcardio's freemium model also allows users to try the app before committing, enhancing its usability appeal.
Clinical Value
PMcardioPMcardio demonstrates superior clinical value with its ability to interpret over 50 cardiac conditions, including critical detections like STEMI/OMI and reduced LVEF, and has been validated in more than 25 studies with reported high accuracy and improved sensitivity over standard methods. iPredict Eye Screening focuses on three retinal diseases (AMD, DR, Glaucoma) and risk prediction for systemic diseases, with reported high accuracy for AMD, but PMcardio's broader diagnostic scope within cardiology and extensive validation give it an edge.
Pricing & Value
PMcardioPMcardio offers a transparent freemium model with a free plan for 5 ECG analyses per month and a Pro Plan for unlimited use, making it accessible for individual clinicians to try and adopt. iPredict Eye Screening requires contacting for pricing, with an estimated per-patient cost of $10-$20, which, while potentially cost-effective for organizations, lacks the immediate transparency and free entry point of PMcardio.
Enterprise Readiness
PMcardioPMcardio is explicitly built for regulated healthcare environments, with SOC 2 Type II, ISO 27001, GDPR, and HIPAA compliance, regional data residency, role-based access control, SSO, and full audit trails. It also offers enterprise integrations with EHR/CVIS and EMS systems. iPredict Eye Screening mentions EHR and telemedicine integration and HIPAA compliance, but PMcardio provides a more comprehensive suite of enterprise-grade security and compliance features.
Innovation
PMcardioPMcardio showcases strong innovation with features like Queen of Heartsu2122 for STEMI/OMI detection, LVsenseu2122 for reduced LVEF detection, and particularly ECGxplainu2122, which provides visual AI explainability with heatmaps, enhancing clinician trust and understanding. While iPredict Eye Screening offers AI-powered screening for multiple retinal and systemic diseases, PMcardio's explainable AI and continuous development in cardiac diagnostics demonstrate a more cutting-edge approach.
Support & Docs
TieBoth tools imply adequate support through their enterprise offerings and regulatory compliance. PMcardio mentions a Help Center and FAQ, and its freemium model allows individual users to explore the app. iPredict Eye Screening's integration with EHR and telemedicine suggests a level of documentation and support for implementation. Without explicit details on the breadth and depth of support and documentation for both tools, it is difficult to definitively pick a winner.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | iPredict Eye Screening | PMcardio |
|---|---|---|
| Name | iPredict Eye Screening | PMcardio |
| Company | iHealthScreen | Powerful Medical |
| Description | iHealthScreen offers an FDA-cleared AI-powered screening tool for age-related macular degeneration (AMD) in patients aged 50 years and older, alongside screening for Diabetic Retinopathy (DR) and Glaucoma. The platform also provides risk prediction for systemic diseases like stroke and heart attack, integrating with EHR and telemedicine services. | PMcardio is a CE-certified AI platform that interprets ECGs to assess over 50 cardiac conditions rapidly and accurately. Clinically validated in more than 25 studies and trusted by over 100,000 clinicians, it delivers rapid, expert-level interpretations, empowering various healthcare professionals to act with confidence at the point of care. |
| Primary Function | AI-powered screening tools for early detection of retinal and systemic diseases. | AI that reads ECGs in seconds |
| Key Features | AI-Based Screening for Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), and Glaucoma; Electronic Health Record (EHR) Solutions; AI-Based Telemedicine Service; Image Analyzer for Retinal Vessel, Retinal Pathology, and OCT Inspector; Online Health Risk Prediction System for Diabetic, Stroke, and Heart Attack patients; Fast results: test completed in less than 5 minutes, report in under 60 seconds; High accuracy: approximately 95% on average (AMD sensitivity 86.86%, specificity 94.13%); Easy to operate, non-invasive, with an advanced touchscreen interface. | Instant AI-powered ECG interpretations; Detection of 50+ ECG findings (including STEMI/OMI, rhythms, reduced LVEF, conduction disorders); Queen of Heartsu2122 - STEMI and OMI Detection; LVsenseu2122 - Reduced LVEF Detection; ECGxplainu2122 - Visual AI Explainability with heatmaps; Core AI - Detects 36 core diagnoses (arrhythmias, conduction blocks, heart blocks, chamber hypertrophies); Automatic analysis of heart rate, axis, P wave, PR, QRS, and QT/QTc intervals; Culprit Artery AI confidence scores with 3D heart visualization. |
Videos
Demos, reviews, and walkthroughs featuring iPredict Eye Screening and PMcardio.